Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant

MLA

Morice, Alyn H., et al. “Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.” Lung, vol. 199, no. 2, Apr. 2021, p. 121. EBSCOhost, https://doi.org/10.1007/s00408-021-00437-7.

APA

Morice, A. H., Birring, S. S., Smith, J. A., McGarvey, L. P., Schelfhout, J., Martin Nguyen, A., & Xu, Z. J. (2021). Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung, 199(2), 121. https://doi.org/10.1007/s00408-021-00437-7

Chicago

Morice, Alyn H., Surinder S. Birring, Jaclyn A. Smith, Lorcan P. McGarvey, Jonathan Schelfhout, Allison Martin Nguyen, and Zhi Jin Xu. 2021. “Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.” Lung 199 (2): 121. doi:10.1007/s00408-021-00437-7.